<a href="https://www.fiercebiotech.com/medtech/tandem-diabetes-issues-software-device-correction-insulin-pump-malfunction" hreflang="en">Tandem Diabetes issues software device correction for insulin pump malfunction </a>
Tandem Diabetes Care has issued an urgent software correction for its Mobi insulin pumps to address a malfunction that can prevent insulin delivery, potentially leading to severe hyperglycemia. The FDA has classified the recall as Class I, affecting over 17,700 devices, with reports of serious injuries but no fatalities.
The most valuable insight for a professional tracking healthtech and medtech developments is the urgent need for software reliability in medical devices like insulin pumps. Tandem Diabetes Care's Class I recall underscores the criticality of robust software systems to prevent malfunctions that can lead to severe patient harm. This highlights an actionable opportunity for investment or innovation in enhancing software QA processes and real-time monitoring systems to ensure device safety and compliance with FDA standards.